Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

FDA Grants Accelerated Approval to Repotrectinib for Adult and Paediatric Patients with NTRK Gene Fusion-positive Solid Tumours

Evidence for efficacy is based on the results from the TRIDENT-1 study
08 Jul 2024
Targeted Therapy;  Molecular Oncology;  Cancer in Adolescents and Young Adults (AYA)

On 13 June 2024, the US Food and Drug Administration granted accelerated approval to repotrectinib (AUGTYRO, Bristol-Myers Squibb Company) for adult and paediatric patients 12 years and older with solid tumours that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, are locally advanced or metastatic or where surgical resection is likely to result in severe morbidity, and that have progressed following treatment or have no satisfactory alternative therapy.

Efficacy was evaluated in TRIDENT-1 (NCT03093116), a multicentre, single-arm, open-label, multi-cohort study in 88 adult patients with locally advanced or metastatic NTRK gene fusion-positive solid tumours who had either received a prior TRK tyrosine kinase inhibitor (TKI) (n=48) or were TKI-naïve (n=40). All patients were assessed for central nervous (CNS) lesions at baseline, and patients with symptomatic brain metastases were excluded. Tumour assessments were performed every 8 weeks.

The major efficacy outcome measures were overall response rate (ORR) and duration of response (DoR) according to RECIST v1.1 as assessed by blinded independent central review. Confirmed ORR in the TKI-naïve group was 58% (95% confidence internal [CI] 41, 73) and 50% (95% CI 35, 65) in the TKI-pretreated group. Median DoR was not estimable (NE; 95% CI NE, NE) in the TKI-naïve group and 9.9 months (95% CI 7.4, 13.0) in the TKI-pretreated group.

The most common (>20%) adverse reactions were dizziness, dysgeusia, peripheral neuropathy, constipation, dyspnoea, fatigue, ataxia, cognitive impairment, muscular weakness, and nausea.

The recommended repotrectinib dose is 160 mg orally once daily for 14 days, then increased to 160 mg twice daily with or without food, until disease progression or unacceptable toxicity.

This review used the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA’s assessment.

This application was granted priority review, fast track designation, breakthrough therapy designation, and orphan drug designation.

Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System.

For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact FDA’s Oncology Center of Excellence Project Facilitate.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.